Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Arfolitixorin Combined With 5-fluorouracil, Oxaliplatin, and Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase 1b/2 Study of Arfolitixorin Combined With 5-fluorouracil, Oxaliplatin, and Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arfolitixorin (Primary) ; Bevacizumab; Fluorouracil; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Isofol Medical

Most Recent Events

  • 20 Jan 2026 According to Isofol Medical media release, An abstract describing the study design for ongoing phase Ib/II clinical study with arfolitixorin has been accepted for presentation at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancer) Symposium in San Francisco, US, January 8-10.
  • 16 Oct 2025 According to Isofol Medical media release, company will present trial design of this study at the European Society for Medical Oncology (ESMO) cancer congress in Berlin, October 17-21.
  • 30 Sep 2025 According to Isofol Medical media release, this study has successfully completed the second dose level of 200 mg/m2 and the company has received clearance from the Safety Review Committee to initiate the next level at 300 mg/m2. In mid-June, the evaluation of the first dose level, 120 mg/m2, was successfully completed. The study can include a maximum of 5 dose levels.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top